Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.

Cancer

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.

Published: May 1991

The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin-2 (IL-2) and gamma-interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL-2 (3.75 x 10(6) cetus units/m2 intravenous bolus three times per week) and gamma-IFN (0.1 mg/m2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma-IFN and IL-2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19910515)67:10<2512::aid-cncr2820671021>3.0.co;2-5DOI Listing

Publication Analysis

Top Keywords

autoantibody formation
8
three times
8
times week
8
antierythrocyte autoantibody
4
formation therapy
4
therapy interleukin-2
4
interleukin-2 gamma-interferon
4
gamma-interferon cardiovascular
4
cardiovascular renal
4
renal pulmonary
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!